BCL10 Antibody (OAEC04238)

Catalog No: OAEC04238

Size:100 ug/100 ul

Western blot analysis using BCL10 mouse mAb against NIH/3T3 (1), Hela (2), MCF-7 (3) and Jurka (4) cell lysate

Immunohistochemical analysis of paraffin-embedded human breast carcinoma (A) and liver carcinoma (B), showing cytoplasmic localization using BCL10mouse mAb with DAB staining.

Confocal immunofluorescence analysis of Hela (left) and NTERA-2 (right) cells using NPM mouse mAb (green). Red: Actin filaments have been labeled with DY-554 phalloidin.

Product Info

• Predicted Species Reactivity: Human, Mouse
• Product Format: Purified antibody in PBS containing 0.03% sodium azide
• Clonality: Monoclonal
• Clone: 4F8
• Isotype: IgG1
• Host: Mouse
• Reconstitution and Storage: Store at 4C, for long term storage, store at -20C.
• Immunogen: Purified recombinant fragment of human BCL-10 expres sed in EColi.
• Concentration: 1 mg/ml
• Application Info: WB: 1/500 - 1/2000
  IHC: 1/200 - 1/1000
  IF: 1/200 - 1/1000
  FC: 1/200 - 1/400
  ELISA: 1/10000
  

Target Info

• Gene Symbol: BCL10
• Gene Full Name: B-cell CLL/lymphoma 10
• Alias Symbols: CLAP, mE10, CIPER, IMD37, c-E10, CARMEN
• NCBI Gene Id: 8915
• Description of Target: Bcl-10 (B-cell CLL/lym phoma 10), also known as CLAP, Me10, CIPER, c-E10, CARME N.Entrez Protein NP_003912. It is a protein containing a caspase recruitment domain (CARD). It plays an important role in apoptosis and activating NF-kappaB. The research suggested that it interacted with other CARD domain containing proteins including CARD9, 10, 11 and14, which were thought to function as upstream regulators in NF-kappaB signaling. Bcl-10 is found to form a complex with MALT1 which encoded by another gene known to be translocated in MALT lym phoma. MALT1 and Bcl-10 are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy.
• Uniprot ID: O95999
• Molecular Weight: 26 kDa